Cargando…
Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea
INTRODUCTION: The quadrivalent inactivated split-virion influenza vaccine (QIV; VaxigripTetra(®)) was initially licensed in South Korea in 2017 for immunization against seasonal influenza in those aged ≥ 3 years, with the indicated age subsequently lowered to include those aged ≥ 6 months in 2018. H...
Autores principales: | Choe, Sunho, Talanova, Oxana, Shin, Sooyoun, Syrkina, Olga, Fournier, Marion |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257373/ https://www.ncbi.nlm.nih.gov/pubmed/37300743 http://dx.doi.org/10.1007/s40121-023-00825-x |
Ejemplares similares
-
Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea
por: Lim, Sookyung, et al.
Publicado: (2022) -
Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults
por: Montomoli, Emanuele, et al.
Publicado: (2018) -
Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022) -
Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®
por: Latreille-Barbier, Mathilde, et al.
Publicado: (2017) -
Assessment of the influenza vaccine (VAXIGRIP) in triggering a humoural immune response
por: Mahallawi, Waleed H.
Publicado: (2017)